Pathogenesis and Bisphosphonate Treatment of Skeletal Events and Bone Pain in Metastatic Cancer: Focus on Ibandronate

  title={Pathogenesis and Bisphosphonate Treatment of Skeletal Events and Bone Pain in Metastatic Cancer: Focus on Ibandronate},
  author={H. B. Sittig},
  journal={Oncology Research and Treatment},
  pages={380 - 387}
  • H. Sittig
  • Published 22 May 2012
  • Medicine
  • Oncology Research and Treatment
Bone metastases are the most common cause of pain in patients with advanced cancer, and are associated with progressive skeletal destruction, spinal problems, and hypercalcaemia. Radiotherapy, analgesia, and surgery are the accepted treatment options for chronic malignant bone pain, with a stepped approach being generally recommended. In the past decade, the bisphosphonates, which reduce bone turnover, increase bone mass, and decrease the risk of fracture, have become established as an… 

Tables from this paper

A multicenter, retrospective epidemiologic survey of the clinical features and management of bone metastatic disease in China
It is suggested that prompt and persistent BP treatment was associated with a reduced risk of SREs and that the proper application of BP was not as common as expected in China.
Bisphosphonate-related osteonecrosis of the jaw: an Italian post-marketing surveillance analysis
This study shows that BRONJ can occur much earlier than hitherto reported, adds new data on BRonJ onset following ibandronate treatment and reveals that patients who cease BP-based therapy develop ONJ, raising the question of post-treatment monitoring strategies.
Oncologists awareness about bisphosphonate related osteonecrosis of the jaws.
A good cooperation of oncologists and dentists is very important to prevent BRONJ.
[Expert consensus on the diagnosis and treatment of bone metastasis in lung cancer (2014 version)].
Expert Consensus on the Diagnosis and Treatment of Bone Metastasis in Lung Cancer (2014 version) Yan SUN, Zhongzhen GUAN, Meilin LIAO, Xin YU, Changli WANG, Jie WANG, Xiaohui NIU, Yuankai SHI, Xiuyi


Use of ibandronate in the prevention of skeletal events in metastatic breast cancer
Ibandronate is a highly potent bisphosphonate available in both intravenous and oral preparations that has been shown in clinical trials to be effective in reducing skeletal complications and also significantly improve quality of life up to 96 weeks.
Metastatic bone pain: treatment options with an emphasis on bisphosphonates
Typically, this syndrome requires moderate baseline analgesia with increased on-demand doses, and therapy with bisphosphonates targeting bone-specific pain is an important strategy.
Oral Bisphosphonates as Adjuvant Therapy for Operable Breast Cancer
Oral bisphosphonate clodronate has been reported to significantly reduce the risk of bone metastases during the 2-year and 5-year study period, which supports its use as additional adjuvant therapy for patients with primary breast cancer.
Ibandronate is effective in preventing skeletal events in patients with bone metastases from colorectal cancer.
Results indicate that ibandronate may be an effective treatment for patients with metastatic bone disease following CRC, and well tolerated with very rare grade 3 or 4 toxicity.
Effects of long-term intravenous ibandronate therapy on skeletal-related events, survival, and bone resorption markers in patients with advanced multiple myeloma.
  • H. Menssen, A. Sakalová, P. Delmas
  • Medicine, Biology
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2002
PURPOSE Bisphosphonates have been found to reduce the incidence of skeletal-related events (SREs) in patients with multiple myeloma. This is the first double-blind, randomized, placebo-controlled
Bone pain reduction in patients with metastatic breast cancer treated with ibandronate–results from a post-marketing surveillance study
Data from this non-interventional study confirm the analgesic efficacy and safety profile of IV and oral ibandronate under real-life conditions.
Efficacy of ibandronate for the treatment of skeletal events in patients with metastatic breast cancer.
Ibandronate was shown to be significantly more effective than placebo as a treatment for metastatic bone disease from breast cancer using multiple end points and was well tolerated with very rare grade 3 or 4 toxicity.
Bisphosphonates for the relief of pain secondary to bone metastases.
Evidence to support the effectiveness of bisphosphonates in providing some pain relief for bone metastases is found and there is insufficient evidence to recommend bisph phosphonates for immediate effect; as first line therapy; or their relative effectiveness for different primary neoplasms.
Radioisotopes for metastatic bone pain.
There is some evidence indicating that radioisotopes may give complete reduction in pain over one to six months with no increase in analgesic use, but adverse effects, specifically leukocy topenia and thrombocytopenia, have also been experienced.